Safety, pharmacokinetics and biodistribution studies of a β-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy

Drug Development and Industrial Pharmacy

Volumn 34, Issue 8, 2008, Pages 789-795

  Devalapally, Harikrishna ^a   Rajan, Kombu Subramanian ^a   Akkinepally, RaghuRam Rao ^a   Devarakonda, Rama Krishna ^a,b  

^a KAKATIYA UNIVERSITY   (India)

^b MEDTRONIC INC   (United States)

Author keywords

ADEPT; Biodistribution; Cancer chemotherapy; Doxorubicin prodrug; Pharmacokinetics; Safety

Indexed keywords

BETA GALACTOSIDE; DOXORUBICIN; N (BETA DEXTRO GLUCOPYRANOSYLBENZYLOXYCARBONYL)DOXORUBICIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; EHRLICH ASCITES TUMOR; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; SURVIVAL TIME; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, EHRLICH TUMOR; DOXORUBICIN; FEMALE; GALACTOSIDES; HALF-LIFE; METABOLIC CLEARANCE RATE; MICE; PRODRUGS; TISSUE DISTRIBUTION;

EID: 49449117347     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701744202     Document Type: Article

References (25)

1. Antoniw, P., Springer, C. J., Bagshawe, K. D., Searle, F., Melton, R. G., & Rogers, G. T., et al. (1990). Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br. J. Cancer, 62, 909-914.
2. Bakina, E., Wu, Z., Rosenblum, M., & Farquhar, D. (1997). Intensely cytotoxic anthracycline prodrugs: glucuronides. J. Med. Chem., 40, 4013-4018.
3. Bosslet, K., Czech, J., & Hoffmann, D. (1994). Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res., 54, 2151-2159.
4. Bosslet, K., Czech, J., & Hoffmann, D. (1995). A novel one-step tumor-selective prodrug activation system. Tumor Targeting, 1, 45-50.
5. Chabner, B. A., Allegra, C. J., Curt, G. A., & Calabresi, P. (1996). Antineoplastic agents. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, L. S. Gilman, & A. Goodman (Eds.), Goodman and Gilman's the pharmacological basis of therapeutics (pp. 1233-1257). New York: McGraw-Hill.
6. Danesi, R., Fogli, S., Gennari, A., Conte, P., & DelTacca, M. (2002). Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin. Pharmacokinet., 41, 431-444.
7. De Graaf, M., Nevalainen, T. J., Scheeren, H. W., Pinedo, H. M., Haisma, H. J., & Boven, E. (2004). A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. Biochem. Pharmacol., 68, 2273-2281.
8. Florent, J. C., Dong, X., Gaudel, G., Mitaku, S., Monneret, C., & Gesson, J. P., et al. (1998). Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem., 41, 3572-3581.
9. Gupta, M., Mazumder, U. K., Rath, N., & Mukhopadhyay, D. K. (2000). Antitumor activity of methanolic extract of Cassia fistula L seed against Ehrlich ascites carcinoma. J. Ethanopharmacol., 72, 151-156.
10. Harikrishna, D., Raghavendra, S. N., Venkateshwarlu, Y., Rao, A.R., & Krishna, D.R. (2007). β-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy. Arch. Pharmacal. Res., 30, 723-732.
11. Harikrishna, D., Rao, A. R., & Krishna, D. R. (2003). Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. Drug News Perspect., 16, 309-318.
12. Hogland, H. C. (1982). Hematological complications of cancer chemotherapy. Semin. Oncol., 9, 95-102.
13. Houba, P. H. J., Boven, E., Van Der Meulen-Muileman, I. H., Leenders, R. G., Scheeren, J. W., & Pinedo, H. M., et al. (1999). Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts. Biochem. Pharmacol., 57, 673-680.
14. Houba, P. H. J., Boven, E., Van Der Meulen-Muileman, I. H., Leenders, R. G. G., Scheeren, J. W., & Pinedo, H. M., et al. (2000). A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br. J. Cancer, 84, 1-8.
15. Krishna, D. R., Sperker, B., Fritz, P., & Klotz, U. (1999). Does pH 6 beta-galactosidase activity indicate cell senescence? Mech. Ageing & Dev., 109, 113-123.
16. Leenders, R. G. G., Damen, E. W., Bijsterveld, E. J., Scheeren, H. W., Houba, P. H., & Van Der Meulen-Muileman, I. H., et al. (1999). Novel anthracycline-spacer-beta-glucuronide,-beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem., 7, 1597-1610.
17. Maseki, M., Nishiagaki, I., Hagishara, M., Tomada, Y., & Yagi, K. (1954). Lipid peroxidation levels and lipid content of serum lipoprotein fractions of pregnant subjects with or without preeclampsia. J. Clin. Chim. Acta, 41, 424-426.
18. Matsuoka, H., Sugimachi, K., Kuwano, H., & Yano, K. (1989). Intratumoural injection of calcium channel blocker enhances cytotoxicity of adriamycin in Ehrlich ascites solid tumour. Eur. J. Surg. Oncol., 15, 224-231.
19. Mazumder, U. K., Gupta, M., Maiti, S., & Mukherjee, M. (1997). Antitumor activity of hygrophilaspinosa on Ehrlich ascites carcinoma and sarcoma-180 induced mice. Ind. J. Expt. Biol., 35, 473-477.
20. Michael, J. B., & Tannock, I. F. (1993). Lysosomes, lysomal enzymes and cancer. Adv. Cancer Res., 60, 269-291.
21. Price, V. E., & Greenfield, R. E. (1958). Anemia in cancer. In: J. P. Greenstein JP, H. A. e. (ed.) Adv. cancer Res., New York, pp 199-200.
22. Qureshi, S., Al-Harbi, M. M., Ahmed, M. M., Raza, M., Giangreco, A. B., & Shah, A. H. (1993). Evaluation of the genotoxic, cytotoxic, and antitumor properties of Commiphora molmol using normal and Ehrlich ascites carcinoma cell-bearing Swiss albino mice. Cancer Chemother. Pharmacol., 33, 130-138.
23. Senter, P. D., & Springer, C. J. (2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev., 53, 247-264.
24. Springer, C. J., Bagshawe, K. D., Sharma, S. K., Searle, F., Boden, J. A., & Antoniw, P., et al. (1991). Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer, 27, 1361-1366.
25. Wallace, P. M., Macmaster, J. F., Smith, V. F., Kerr, D. E., Senter, P. D., & Cosand, W. L. (1994). Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res., 54, 2719-2723.